I have felt for a couple of years that this is a very interesting biotech heading toward two phase 3 studies next year that both will have short time data collection periods leading to possible major deciions.
Company history highlighted by 50 years of research in the Pacific region.
May 6 company conference call initiated a sell off that seems to be a good entry point unless someone can explain to me what item in the call initiated the sell off. I cannot detect a red flag in the transcript of the call.
Not a terrible first day for a new secondary issuance; stock recovered almost 50% from a 9% sell off in pre-market. I want to learn more about the quality/reputation of the acquirers. If the likes of Wainwright or other hatchet shops are involved, we all know how this will turn out. Prefer buying at support sub $4, but a temp floor may now be in. We'll see.
My understanding is that there is a new process in Australia that can accelerate the approval of promising drugs after a successful Phase 2 study whereby you can begin selling the drug and continue collecting data into a phase 4 to achieve final approval.
Since DMAC increased the stroke study to 100 patients which is supposed to report topline phase 2 results data in 1Q/20, I'm wondering if they are applying for this "provisional approval?"
Any information or thoughts about this possibility would be appreciated.
Anyone know where to find a list of the owners of this company...particularly the owners of the largest percentage of shares. Conference call indicated there were at least two Chinese entities who owned shares, but all I see in the SEC filings of institutional owners are not Chinese??
“The compound is used in Asia for an astonishing list of diseases, despite the fact that it’s extremely expensive.
The Asian form is also suboptimal as a Western drug candidate because it comes from pig pancreases and the urine of young humans. Using animal or urine sources is not just aesthetically distasteful, it introduces risks of contamination into the production process that tend to put off regulators.
DiaMedica solved that problem by developing a proprietary, genetically modified cell type that expresses enormous amounts of KLK1 at a fraction of the cost of existing cell technologies. Big Pharma had tried to do this for years, always failing.
These cells have allowed DiaMedica to synthesize a drug under standardized conditions that has enormous potential—not only as treatments for many diseases, but as a breakthrough anti-aging geroprotector”
“Think of recombinant tissue kallikrein, DiaMedica’s lead product, as being a blood-vessel opening, blood-flow promoting substance that is nature’s preferred way of enhancing perfusion (flow) in tissues. You don’t have to be a rocket scientist to think of disease states where flow is aberrant or altered or needs assistance, right? What if recombinant tissue kallikrein had a role in all or many of those settings? Stroke, heart attack, peripheral vascular disease, angina, hypertension, maybe even PULMONARY hypertension.”